Retracted: Clinical Importance of Somatostatin Receptor 2 (SSTR2) and Somatostatin Receptor 5 (SSTR5) Expression in Thyrotropin-Producing Pituitary Adenoma (TSHoma)

撤稿:生长抑素受体 2 (SSTR2) 和生长抑素受体 5 (SSTR5) 在促甲状腺激素分泌性垂体腺瘤 (TSHoma) 中的表达的临床意义

阅读:2

Abstract

In the article entitled, "Clinical Importance of Somatostatin Receptor 2 (SSTR2) and Somatostatin Receptor 5 (SSTR5) Expression in Thyrotropin-Producing Pituitary Adenoma (TSHoma)", which was published in Medical Science Monitor 2017-04-23, Med Sci Monit 2017; 23: 1947-1955, the text has been directly copied from a previously published article entitled, "Immunohistochemical expression of somatostatin receptor subtypes 2 and 5 in thyrotropin-secreting pituitary adenomas: a consecutive case series of pituitary adenomas" by Hong-Juan Fang, Yang-Fang Li, Yu Fu, Li-Yong Zhong, and Ya-Zhuo Zhan in Int J Clin Exp Pathol 2017;10(1): 479-488 (www.ijcep.com /ISSN: 1936-2625/IJCEP0042895). Thus, owing to the duplicity of text, the article is being retracted.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。